Ayalew Tefferi Selected Research

Biomarkers (Surrogate Marker)

4/2024	Methodological challenges in the development of endpoints for myelofibrosis clinical trials.
12/2023	A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.
10/2022	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.
1/2021	Development and application of novel immunoassays for eosinophil granule major basic proteins to evaluate eosinophilia and myeloproliferative disorders.
4/2012	Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.
4/2008	JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
10/2005	Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ayalew Tefferi Research Topics

Disease

138	Primary Myelofibrosis (Myelosclerosis) 04/2024 - 01/2002
90	Neoplasms (Cancer) 01/2024 - 02/2002
48	Anemia 01/2024 - 12/2002
46	Splenomegaly 04/2024 - 06/2002
43	Essential Thrombocythemia 05/2024 - 01/2004
43	Polycythemia Vera 10/2018 - 04/2002
37	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2024 - 08/2002
34	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 03/2024 - 03/2003
26	Leukemia 03/2024 - 01/2002
26	Myeloproliferative Disorders (Myeloproliferative Disorder) 01/2021 - 01/2003
22	Systemic Mastocytosis 01/2022 - 11/2002
21	Eosinophilia 04/2024 - 05/2002
20	Thrombosis (Thrombus) 01/2024 - 05/2003
20	Thrombocytosis (Thrombocythemia) 01/2024 - 05/2002
19	Hematologic Neoplasms (Hematological Malignancy) 11/2022 - 02/2002
18	Thrombocytopenia (Thrombopenia) 01/2024 - 12/2002
18	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2023 - 01/2002
17	Fibrosis (Cirrhosis) 01/2023 - 03/2002
14	Pruritus (Itching) 01/2023 - 04/2002
14	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 06/2004
13	Cytopenia 04/2024 - 01/2002
13	Hypereosinophilic Syndrome (Loeffler Endocarditis) 02/2010 - 05/2002
12	Cachexia 01/2024 - 07/2004
11	Pain (Aches) 01/2023 - 05/2004
10	Polycythemia (Erythrocytosis) 11/2023 - 03/2005
10	Venous Thrombosis (Deep-Vein Thrombosis) 01/2023 - 06/2006
9	Leukocytosis (Pleocytosis) 03/2024 - 01/2003
8	Pdgfra-Associated Chronic Eosinophilic Leukemia 03/2010 - 06/2004
7	Blast Crisis (Blast Phase) 01/2023 - 01/2018
7	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 03/2003
6	Chronic Neutrophilic Leukemia 01/2021 - 08/2005
6	Portal Hypertension 11/2018 - 08/2005
6	Pulmonary Hypertension 12/2016 - 09/2002
5	Hemorrhage 01/2020 - 01/2004
5	Osteosclerosis 01/2006 - 01/2003
4	Disease Progression 01/2024 - 02/2005
4	Abnormal Karyotype 01/2022 - 01/2012
4	Lymphoma (Lymphomas) 11/2020 - 01/2006
4	Neutropenia 02/2019 - 09/2008
4	Hepatomegaly 12/2016 - 02/2005
4	Mast Cell Activation Disorders (Mast-Cell Disease) 03/2010 - 01/2002
4	Immunoglobulin Light-chain Amyloidosis 02/2005 - 11/2002

Drug/Important Bio-Agent (IBA)

32	Hemoglobins (Hemoglobin)IBA 11/2023 - 12/2002
29	CytokinesIBA 11/2023 - 02/2002
24	ruxolitinibIBA 02/2024 - 09/2009
22	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2021 - 07/2003
22	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 01/2002
20	Janus Kinase InhibitorsIBA 04/2024 - 09/2010
18	venetoclaxIBA 03/2024 - 11/2020
15	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 03/2003
14	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2024 - 02/2003
14	Janus Kinase 2IBA 01/2024 - 08/2005
13	CalreticulinIBA 01/2024 - 08/2014
13	Erythropoietin FDA Link 01/2023 - 01/2003
12	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 03/2003
12	Prednisone (Sone)FDA LinkGeneric 01/2021 - 03/2003
12	Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA 03/2016 - 11/2003
11	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 03/2024 - 03/2011
11	Lenalidomide (CC 5013)FDA Link 03/2024 - 08/2006
11	Thalidomide (Thalomid)FDA Link 01/2021 - 05/2002
9	fedratinibIBA 01/2024 - 04/2008
9	Reticulin (Reticular Fiber)IBA 01/2023 - 06/2002
8	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 02/2010 - 05/2003
7	Biomarkers (Surrogate Marker)IBA 04/2024 - 10/2005
7	Cladribine FDA LinkGeneric 03/2024 - 03/2003
7	CollagenIBA 01/2023 - 01/2003
7	pomalidomideIBA 01/2021 - 09/2009
7	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2014 - 01/2003
7	Phosphotransferases (Kinase)IBA 07/2011 - 01/2002
6	HematinicsIBA 01/2023 - 08/2009
6	luspaterceptIBA 01/2023 - 01/2019
6	Interferon-alpha (Interferon Alfa)IBA 01/2021 - 01/2005
6	AndrogensIBA 01/2021 - 01/2003
5	Alkaline PhosphataseIBA 09/2023 - 11/2002
5	Tyrosine Kinase InhibitorsIBA 01/2023 - 08/2007
5	Busulfan (Busulfex)FDA Link 06/2022 - 04/2015
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2016 - 07/2005
5	Indicators and Reagents (Reagents)IBA 12/2013 - 02/2005
4	Tryptases (Tryptase)IBA 01/2024 - 10/2003
4	Glucose (Dextrose)FDA LinkGeneric 11/2023 - 01/2023
4	SodiumIBA 11/2023 - 01/2023
4	Decitabine FDA Link 11/2023 - 01/2019
4	nilotinib FDA Link 11/2023 - 08/2007
4	ponatinibIBA 11/2023 - 01/2018
4	Oxygen (Dioxygen)IBA 01/2023 - 05/2018
4	Ferritins (Ferritin)IBA 01/2023 - 08/2008
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2022 - 06/2003
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2008
4	anagrelide (Agrylin)FDA LinkGeneric 01/2019 - 11/2004
4	AnticoagulantsIBA 03/2013 - 08/2004

Therapy/Procedure

126	Therapeutics 04/2024 - 01/2002
23	Splenectomy 03/2024 - 09/2003
18	Drug Therapy (Chemotherapy) 01/2023 - 11/2002
15	Radiotherapy 03/2024 - 09/2002
10	Stem Cell Transplantation 12/2023 - 11/2002
6	Hematopoietic Stem Cell Transplantation 01/2024 - 05/2003
5	Transplantation 03/2024 - 07/2004
4	Induction Chemotherapy 10/2022 - 12/2007
4	Erythrocyte Transfusion 04/2014 - 07/2004
4	Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation) 11/2004 - 04/2003